amphetamine has been researched along with Chronic Disease in 41 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the article the authors present the pathological features of chronic toxic osteomyelitis in drug addicts taking amphetamine of handicraft production (pervitin, vint)." | 7.79 | [Pathomorphological features of chronic toxic osteomyelitis in drug addicts taking amphetamine of a street drugs brand]. ( Miroshnichenko, MS; Pliten', ON; Ruzin, GP; Tkachenko, OV, 2013) |
| "Chronic fatigue is a complex and little understood symptom for which there is no safe and effective pharmacotherapy." | 5.33 | Trichopus zeylanicus combats fatigue without amphetamine-mimetic activity. ( Brown-Borg, HM; Dhanasekaran, M; Manyam, BV; Tharakan, B, 2006) |
| "In the article the authors present the pathological features of chronic toxic osteomyelitis in drug addicts taking amphetamine of handicraft production (pervitin, vint)." | 3.79 | [Pathomorphological features of chronic toxic osteomyelitis in drug addicts taking amphetamine of a street drugs brand]. ( Miroshnichenko, MS; Pliten', ON; Ruzin, GP; Tkachenko, OV, 2013) |
| "Labetalol is commonly used for control of hypertension in pregnancy." | 3.77 | False-positive amphetamine toxicology screen results in three pregnant women using labetalol. ( Wu, D; Yee, LM, 2011) |
| "Amphetamine, methamphetamine, and cocaine are suspected of being pulmonary hypertension risk factors based on a small number of case reports along with pharmacologic similarities to fenfluramine, a diet drug associated with pulmonary arterial hypertension (PAH)." | 3.73 | Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? ( Channick, RN; Chin, KM; Rubin, LJ, 2006) |
| "Chronic fatigue is a complex and little understood symptom for which there is no safe and effective pharmacotherapy." | 1.33 | Trichopus zeylanicus combats fatigue without amphetamine-mimetic activity. ( Brown-Borg, HM; Dhanasekaran, M; Manyam, BV; Tharakan, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (46.34) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 11 (26.83) | 29.6817 |
| 2010's | 8 (19.51) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, S | 1 |
| Luo, J | 1 |
| Zeng, Y | 1 |
| Ren, H | 1 |
| Chen, Z | 1 |
| Ren, Y | 1 |
| Anderson, EM | 1 |
| McFadden, LM | 1 |
| Matuszewich, L | 1 |
| McFarland, R | 1 |
| Wang, ZT | 1 |
| Jouroukhin, Y | 1 |
| Li, Y | 2 |
| Mychko, O | 1 |
| Coppens, I | 1 |
| Xiao, J | 2 |
| Jones-Brando, L | 1 |
| Yolken, RH | 2 |
| Sibley, LD | 1 |
| Pletnikov, MV | 2 |
| Ruzin, GP | 1 |
| Tkachenko, OV | 1 |
| Miroshnichenko, MS | 1 |
| Pliten', ON | 1 |
| Prandovszky, E | 1 |
| Kannan, G | 1 |
| Viscidi, RP | 1 |
| Vonder Haar, C | 1 |
| Lam, FC | 1 |
| Adams, WK | 1 |
| Riparip, LK | 1 |
| Kaur, S | 1 |
| Muthukrishna, M | 1 |
| Rosi, S | 1 |
| Winstanley, CA | 1 |
| Pietrzak, RH | 1 |
| Snyder, PJ | 1 |
| Maruff, P | 1 |
| Yee, LM | 1 |
| Wu, D | 1 |
| Cantrup, R | 1 |
| Sathanantham, K | 1 |
| Rushlow, WJ | 1 |
| Rajakumar, N | 1 |
| Gray, NS | 1 |
| Pickering, AD | 1 |
| Snowden, RJ | 1 |
| Hemsley, DR | 1 |
| Gray, JA | 1 |
| Lin, D | 1 |
| Bruijnzeel, AW | 1 |
| Schmidt, P | 1 |
| Markou, A | 1 |
| Jain, S | 1 |
| Sharma, R | 1 |
| Bisagno, V | 1 |
| Grillo, CA | 1 |
| Piroli, GG | 1 |
| Giraldo, P | 1 |
| McEwen, B | 1 |
| Luine, VN | 1 |
| Tharakan, B | 1 |
| Dhanasekaran, M | 1 |
| Brown-Borg, HM | 1 |
| Manyam, BV | 1 |
| Chin, KM | 1 |
| Channick, RN | 1 |
| Rubin, LJ | 1 |
| Rank, MM | 1 |
| Li, X | 1 |
| Bennett, DJ | 1 |
| Gorassini, MA | 1 |
| Oswald, LM | 1 |
| Wong, DF | 1 |
| Zhou, Y | 1 |
| Kumar, A | 1 |
| Brasic, J | 1 |
| Alexander, M | 1 |
| Ye, W | 1 |
| Kuwabara, H | 1 |
| Hilton, J | 1 |
| Wand, GS | 1 |
| Spector, R | 1 |
| Yukitake, A | 1 |
| Johansson, BB | 1 |
| Katz, RJ | 1 |
| Roth, KA | 1 |
| Schmaltz, K | 1 |
| Flaum, M | 1 |
| Schultz, SK | 1 |
| Capriles, N | 1 |
| Cancela, LM | 1 |
| Saito, T | 1 |
| Yamamoto, I | 1 |
| Kusakabe, T | 1 |
| Huang, X | 1 |
| Yukawa, N | 1 |
| Takeichi, S | 1 |
| Kalasinsky, KS | 1 |
| Bosy, TZ | 1 |
| Schmunk, GA | 1 |
| Reiber, G | 1 |
| Anthony, RM | 1 |
| Furukawa, Y | 1 |
| Guttman, M | 1 |
| Kish, SJ | 1 |
| Laviola, G | 1 |
| Adriani, W | 1 |
| Morley-Fletcher, S | 1 |
| Terranova, ML | 1 |
| Langer, G | 1 |
| Heinze, G | 1 |
| Reim, B | 1 |
| Matussek, N | 1 |
| Bergen, JR | 1 |
| Mulhall, S | 1 |
| Moorman, P | 1 |
| Sudilovsky, A | 1 |
| Wolkin, A | 1 |
| Angrist, B | 1 |
| Wolf, A | 1 |
| Brodie, J | 1 |
| Wolkin, B | 1 |
| Jaeger, J | 1 |
| Cancro, R | 1 |
| Rotrosen, J | 1 |
| Caldecott-Hazard, S | 1 |
| Mazziotta, J | 1 |
| Phelps, M | 1 |
| Spotts, JV | 1 |
| Shontz, FC | 1 |
| Jefferson, JW | 1 |
| Schofferman, J | 1 |
| Billesdon, J | 1 |
| Hall, R | 1 |
| Cesarec, Z | 1 |
| Eberhard, G | 1 |
| Nordgren, L | 1 |
| Fischer, U | 1 |
| Fischer, B | 1 |
| Price, J | 1 |
| Hopkinson, G | 1 |
| Tucker, GJ | 1 |
| Quinlan, D | 1 |
| Harrow, M | 1 |
| Matveĭchuk, TS | 1 |
| Rockwell, DA | 1 |
| Milman, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
4 reviews available for amphetamine and Chronic Disease
| Article | Year |
|---|---|
The blood-brain barrier in acute and chronic hypertension.
Topics: Acute Disease; Amphetamine; Animals; Barbiturates; Blood Pressure; Blood-Brain Barrier; Cell Membran | 1980 |
Peculiar response of adolescent mice to acute and chronic stress and to amphetamine: evidence of sex differences.
Topics: Acute Disease; Aging; Amphetamine; Animals; Central Nervous System Stimulants; Chronic Disease; Cort | 2002 |
Beta-adrenergic receptor blocking drugs in psychiatry.
Topics: Acute Disease; Adrenergic beta-Antagonists; Alcoholism; Amphetamine; Animals; Antidepressive Agents; | 1974 |
Mono-amine oxidase inhibitors and schizophrenia.
Topics: Acute Disease; Amines; Amphetamine; Chronic Disease; Hallucinogens; Humans; Iproniazid; Isoniazid; M | 1968 |
5 trials available for amphetamine and Chronic Disease
| Article | Year |
|---|---|
Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects.
Topics: Adult; Amphetamine; Chronic Disease; Cognition; Diagnostic and Statistical Manual of Mental Disorder | 2010 |
The partial reinforcement extinction effect in humans: effects of schizophrenia, schizotypy and low doses of amphetamine.
Topics: Acute Disease; Adult; Amphetamine; Central Nervous System Stimulants; Chronic Disease; Dose-Response | 2002 |
Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography.
Topics: Adult; Amphetamine; Brain; Brain Chemistry; Chronic Disease; Humans; Kinetics; Male; Middle Aged; Sc | 1987 |
Beta-adrenergic receptor blocking drugs in psychiatry.
Topics: Acute Disease; Adrenergic beta-Antagonists; Alcoholism; Amphetamine; Animals; Antidepressive Agents; | 1974 |
A controlled study of the antipsychotic and sedative effects of neuroleptic drugs and amphetamine in chronic schizophrenics. A clinical and experimental-psychological study.
Topics: Adult; Amphetamine; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Depressi | 1974 |
33 other studies available for amphetamine and Chronic Disease
| Article | Year |
|---|---|
Acupuncture for protracted amphetamine abstinence syndrome: study protocol for a systematic review and meta-analysis.
Topics: Acupuncture Therapy; Amphetamine; Chronic Disease; Humans; Meta-Analysis as Topic; Neoplasm Recurren | 2023 |
Interaction of stress and stimulants in female rats: Role of chronic stress on later reactivity to methamphetamine.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Chronic Dise | 2019 |
AAH2 gene is not required for dopamine-dependent neurochemical and behavioral abnormalities produced by Toxoplasma infection in mouse.
Topics: Amphetamine; Animals; Animals, Genetically Modified; Astrocytes; Brain; Central Nervous System Stimu | 2018 |
[Pathomorphological features of chronic toxic osteomyelitis in drug addicts taking amphetamine of a street drugs brand].
Topics: Adult; Amphetamine; Chronic Disease; Drug Users; Eosine Yellowish-(YS); Hematoxylin; Histocytochemis | 2013 |
Behavioral Abnormalities in a Mouse Model of Chronic Toxoplasmosis Are Associated with MAG1 Antibody Levels and Cyst Burden.
Topics: Amphetamine; Animals; Animals, Outbred Strains; Antibodies, Protozoan; Brain; Central Nervous System | 2016 |
Frontal Traumatic Brain Injury in Rats Causes Long-Lasting Impairments in Impulse Control That Are Differentially Sensitive to Pharmacotherapeutics and Associated with Chronic Neuroinflammation.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Amantadine; Amphetamine; Animals; Atomoxetine Hydrochlo | 2016 |
False-positive amphetamine toxicology screen results in three pregnant women using labetalol.
Topics: Adult; Amphetamine; Antihypertensive Agents; Cesarean Section; Chronic Disease; Cocaine; Cross React | 2011 |
Chronic hyperdopaminergic activity of schizophrenia is associated with increased ΔFosB levels and cdk-5 signaling in the nucleus accumbens.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Apomorphine; Blotting, Western; Chroni | 2012 |
Exposure to chronic mild stress alters thresholds for lateral hypothalamic stimulation reward and subsequent responsiveness to amphetamine.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Chronic Dise | 2002 |
Analgesia in phasic and tonic pain tests in a pharmacological model of autotomy.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amphetamine; Analgesia; Animals; Behavio | 2002 |
Chronic stress alters amphetamine effects on behavior and synaptophysin levels in female rats.
Topics: Amphetamine; Animals; Chronic Disease; Corticosterone; Exploratory Behavior; Female; Hippocampus; Mo | 2004 |
Trichopus zeylanicus combats fatigue without amphetamine-mimetic activity.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Chronic Disease; Dioscoreaceae; Fatigu | 2006 |
Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?
Topics: Adult; Amphetamine; California; Central Nervous System Stimulants; Chronic Disease; Cocaine; Drug In | 2006 |
Role of endogenous release of norepinephrine in muscle spasms after chronic spinal cord injury.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Anesthetics, Local; Animals; Anterior Horn Cells; Chronic | 2007 |
Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release.
Topics: Adult; Amphetamine; Carbon Radioisotopes; Central Nervous System Stimulants; Chronic Disease; Corpus | 2007 |
Treatment of moderate & severe chronic pain syndromes with morphine & adjunctive drugs.
Topics: Amphetamine; Chronic Disease; Cocaine; Doxapram; Histamine H1 Antagonists; Humans; Morphine; Narcoti | 1981 |
Amphetamine psychosis in Tokyo--its clinical features and social problems.
Topics: Acute Disease; Adult; Amphetamine; Chronic Disease; Diagnosis, Differential; Female; Humans; Male; M | 1983 |
Amphetamine and tranylcypromine in an animal model of depression: pharmacological specificity of the reversal effect.
Topics: Amphetamine; Animals; Chronic Disease; Corticosterone; Defecation; Depression; Disease Models, Anima | 1981 |
When does amphetamine-induced psychosis become schizophrenia?
Topics: Adult; Amphetamine; Amphetamines; Chronic Disease; Humans; Male; Psychoses, Substance-Induced; Schiz | 1996 |
Effect of acute and chronic stress restraint on amphetamine-associated place preference: involvement of dopamine D(1) and D(2) receptors.
Topics: Acute Disease; Adaptation, Psychological; Amphetamine; Analysis of Variance; Animals; Chronic Diseas | 1999 |
Determination of chronic methamphetamine abuse by hair analysis.
Topics: Adult; Amphetamine; Asthma; Bronchodilator Agents; Central Nervous System Stimulants; Chronic Diseas | 2000 |
Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users.
Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Autopsy; Brain; Brain Chemistry; Cause of Death; | 2001 |
Reduced growth hormone responses to amphetamine in "endogenous" depressive patients: studies in normal, "reactive" and "endogenous" depressive, schizophrenic, and chronic alcoholic subjects.
Topics: Adjustment Disorders; Adult; Aged; Alcoholism; Amphetamine; Blood Pressure; Chronic Disease; Depress | 1976 |
Comparison of 3,4-dimethoxyphenylethylamine treated plasma from chronic schizophrenics and controls.
Topics: Amphetamine; Animals; Behavior, Animal; Biogenic Amines; Blood; Brain Chemistry; Chronic Disease; Cr | 1975 |
Disruption of behavior in cats by chronic amphetamine intoxication.
Topics: Amphetamine; Animals; Behavior; Cats; Chronic Disease; Humans; Movement Disorders; Stereotyped Behav | 1975 |
Cerebral correlates of depressed behavior in rats, visualized using 14C-2-deoxyglucose autoradiography.
Topics: alpha-Methyltyrosine; Amphetamine; Animals; Autoradiography; Behavior, Animal; Brain; Carbon Radiois | 1988 |
A new perspective on intervention in heavy, chronic drug use.
Topics: Amphetamine; Chronic Disease; Cocaine; Dependency, Psychological; Ego; Female; Humans; Hypnotics and | 1985 |
Microangiopathic hemolytic anemia. Another complication of drug abuse.
Topics: Adult; Amphetamine; Anemia, Hemolytic; Barbiturates; Biopsy; Chronic Disease; Foreign Bodies; Foreig | 1974 |
[Drug dependence. 1. Definition, narcotic agent, mode of action and hazards].
Topics: Adolescent; Adult; Amphetamine; Cannabis; Chronic Disease; Cocaine; Condiments; Female; Heroin; Hero | 1973 |
Chronic hallucinogenic drug use and thought disturbance.
Topics: Adolescent; Adult; Amphetamine; Cannabis; Chronic Disease; Cognition Disorders; Female; Hallucinogen | 1972 |
[Use of a combination of methionine and various psychotropic drugs in the treatment of chronic schizophrenia patients].
Topics: Amphetamine; Chronic Disease; Humans; Iproniazid; Methionine; Monoamine Oxidase Inhibitors; Schizoph | 1969 |
Amphetamine abuse by hospitalized chronic schizophrenic patients.
Topics: Amphetamine; Chromatography, Thin Layer; Chronic Disease; Hospitalization; Hospitals, Psychiatric; H | 1968 |
The role of maribuana in patterns of drug abuse by adolescents.
Topics: Adolescent; Adult; Aggression; Amphetamine; Barbiturates; Cannabis; Catatonia; Chronic Disease; Diss | 1969 |